Halozyme Therapeutics Interest Expense Over Time
| HALO Stock | USD 48.20 0.27 0.56% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Halozyme Therapeutics Performance and Halozyme Therapeutics Correlation. Halozyme |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Halozyme Therapeutics. If investors know Halozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Halozyme Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.721 | Earnings Share 3.02 | Revenue Per Share 7.431 | Quarterly Revenue Growth 0.343 | Return On Assets 0.1487 |
The market value of Halozyme Therapeutics is measured differently than its book value, which is the value of Halozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Halozyme Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Halozyme Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Halozyme Therapeutics' market value can be influenced by many factors that don't directly affect Halozyme Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Halozyme Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Halozyme Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Halozyme Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Interest Expense Analysis
Compare Halozyme Therapeutics and related stocks such as Agios Pharm, Insmed Inc, and Cerevel Therapeutics Interest Expense Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AGIO | 132 K | 132 K | 69 K | 55 K | 203 K | 968 K | 2.5 M | 6.1 M | 16.5 M | 14.9 M | 17.8 M | 836 K | 12.8 M | 14.7 M | 15.4 M |
| INSM | 0.0 | 10 K | 763 K | 2.4 M | 2.4 M | 2.9 M | 3.5 M | 5.9 M | 25.5 M | 27.7 M | 29.6 M | 40.5 M | 26.4 M | 81.7 M | 85.8 M |
| RARE | 270 K | 270 K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.1 M | 33.3 M | 29.4 M | 43 M | 66 M | 69.3 M |
| BMRN | 0.0 | 8.3 M | 7.6 M | 10.4 M | 36.6 M | 38.2 M | 39.5 M | 42.7 M | 43.7 M | 23.5 M | 29.3 M | 15.3 M | 16 M | 17.3 M | 18 M |
| ALNY | 0.0 | 1.2 M | 977 K | 1.1 M | 2.6 M | 5.9 M | 8.3 M | 12.2 M | 29.3 M | 108.5 M | 84.5 M | 143 M | 156 M | 121.2 M | 127.3 M |
| EXEL | 0.0 | 16.3 M | 27.1 M | 45.3 M | 41.4 M | 40.7 M | 33.1 M | 8.7 M | 0.0 | 0.0 | 0.0 | 0.0 | 53.7 M | 61.8 M | 64.9 M |
| ALEC | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 8.3 M | 16.2 M | 18.7 M | 19.6 M |
| LEGN | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 82 K | 223 K | 4.2 M | 900 K | 10.8 M | 21.8 M | 22.9 M |
| ASND | 20 K | 20 K | 20 K | 8 K | 16 K | 6 K | 5 K | 97 K | 127 K | 1.2 M | 1.9 M | 3.9 M | 50.5 M | 44.1 M | 46.3 M |
| CYTK | 267 K | 104 K | 87 K | 177 K | 108 K | 94 K | 2.2 M | 17 M | 21.6 M | 27.4 M | 38.7 M | 29.3 M | 51.2 M | 57.7 M | 60.6 M |
| EWTX | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 69 K | 272 K | 4 M | 4.6 M | 4.9 M |
| APLS | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 96.9 K | 2.5 M | 5.3 M | 29.9 M | 13.2 M | 32.6 M | 29.6 M | 31.1 M |
| BPMC | 138 K | 138 K | 138 K | 138 K | 453 K | 696 K | 469 K | 221 K | 73 K | 13.7 M | 12.8 M | 7.4 M | 16.8 M | 51.6 M | 54.2 M |
| BGNE | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.6 M | 1.2 M | 383 K | 4.1 M | 13.9 M | 9.1 M | 338 K | 15.8 M | 52.5 M | 37.4 M | 39.2 M |
| INBX | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.1 M | 1.5 M | 5.7 M | 10.8 M | 5.2 M | 16.1 M | 31.8 M | 33.4 M |
| PTGX | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 169 K | 598 K | 2.5 M | 3.4 M | 3.9 M | 4.1 M |
| LRMR | 870 K | 870 K | 870 K | 870 K | 870 K | 473 K | 347 K | 971 K | 246 K | 1.8 M | 0.0 | 326 K | 318 K | 286.2 K | 472.6 K |
| VRDN | 1.6 M | 1.6 M | 1.6 M | 2 M | 1 M | 141 K | 95 K | 383 K | 873 K | 835 K | 508 K | 3 K | 486 K | 1.8 M | 1.9 M |
Halozyme Therapeutics and related stocks such as Agios Pharm, Insmed Inc, and Cerevel Therapeutics Interest Expense description
The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.My Equities
My Current Equities and Potential Positions
| Halozyme Therapeutics | HALO |
| Classification | Cancer Fighters |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 48.2
Check out Halozyme Therapeutics Performance and Halozyme Therapeutics Correlation. To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Halozyme Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.